Point72 Hong Kong LTD Geron Corp Transaction History

Point72 Hong Kong LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.67 - $2.94 $12,869 - $22,655	7,706 New	7,706 $18,000
Q1 2022 May 16, 2022	SELL	$0.99 - $1.6 $11,211 - $18,120	-11,325 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.22 - $1.72 $13,816 - $19,479	11,325 New	11,325 $14,000
Q2 2021 Aug 16, 2021	SELL	$1.25 - $1.83 $7,866 - $11,516	-6,293 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$1.52 - $2.1 $8,843 - $12,217	-5,818 Reduced 48.04%	6,293 $10,000
Q4 2020 Feb 16, 2021	BUY	$1.55 - $2.05 $7,464 - $9,872	4,816 Added 66.02%	12,111 $19,000
Q3 2020 Nov 16, 2020	BUY	$1.59 - $2.19 $3,788 - $5,218	2,383 Added 48.51%	7,295 $13,000
Q2 2020 Aug 14, 2020	BUY	$1.05 - $2.18 $5,157 - $10,708	4,912 New	4,912 $11,000
Q4 2018 Feb 14, 2019	SELL	$0.98 - $1.85 $11,870 - $22,409	-12,113 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$1.76 - $6.38 $21,318 - $77,280	12,113 New	12,113 $21,000

274

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.32B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.